Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumoia

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This was a randomized, double-blind, placebo-controlled parallel study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Zhejiang University

Criteria

Inclusion Criteria:

• 18 years of age, male or female;

• History of COVID-19 infection within 1 week;

• Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min.

• Clear consciousness, Capable and voluntary informed consent.

Exclusion Criteria:

• Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption;

• Any person meeting criteria for critical pneumonia;

• Patients considered unsuitable for this trial by the investigator.